Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of recombinant human coagulation factor VIII for on-demand bleeding treatment and perioperative replacement therapy in previously treated severe hemophilia A
CTR20242956Phase 3Completed
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human coagulation factor VIII in hemophilia A, sponsored by Nanjing Shunxin Pharmaceutical. Started Nov 2024; status: completed.
02
Drugs
recombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20242956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242956.